Infectious disease
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Inside the U.S., the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 began today.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
Arie Belldegrun, the co-founder and executive chairman of the board of Allogene, disclosed this weekend that he has been diagnosed with COVID-19. The pharma entrepreneur is in self-quarantine and is doing well.
Canada’s Medicago announced Thursday it has successfully produced a Virus-Like Particle of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene. The company is now focused on developing a vaccine for COVID-19, the virus caused by SARS-CoV-2.
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution.
Hospitals and laboratories will be able to run the test on Roche’s fully automated cobas 6800 and cobas 8800 Systems, which are already in wide use in the U.S. and internationally.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
More flexible versions of the COVID-19 diagnostic tests are being developed but, currently, are only available for research.
Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.
PRESS RELEASES